About TherOx
TherOx is a Healthcare company based in Irvine (United States) founded in 1995, and was acquired by ZOLL AEDs in June 2019. Super saturated oxygen therapy for reducing cardiac muscle damage. TherOx has raised $113.44 million across 7 funding rounds from investors including Kleiner Perkins, ZOLL AEDs and Tekla Capital Management. The company has 17 employees. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is THEROX, INC. Its competitors include Precise Bio, Nirva Medical and Nininger Medical; 2 of its 3 listed competitors have raised funding.
Company details
TherOx is a private medical device company which has developed the super-saturated oxygen (SSO2) therapy system and cartridge. The intent of this therapy is to salvage damaged heart tissue by placing a high concentration of oxygen into the patients blood plasma and delivering it directly to the area impacted by the heart attack. It is used as a complement to percutaneous coronary intervention and stenting. The product is yet to receive FDA approval. The company is backed by Kleiner Perkins Caufield and Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners, DAG Ventures and Cross Creek Capital.
- Headquarters Irvine, United States
- Employees 17
- Stage Acquired
- SectorsHealthcare
- Website therox.com
- Social LinkedIn
- Acquired by ZOLL AEDs (Jun 2019)
- Legal Name Therox, Inc.
- Total Equity Funding$113.44M (USD)
in 7 rounds
- Latest Funding Round$15M (USD), Debt – Conventional
May 2018
- InvestorsKleiner Perkins
& 8 more
- Employee Count17
- Acquired byZOLL AEDs
(Jun 2019)
Funding Insights of TherOx
TherOx has successfully raised a total of $113.44M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $15 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $113.44M
- Total Rounds 7
- Last Round Debt – Conventional — $15M
- First Round $30M
(Dec 2000)
- Investors Count 9
All 7 funding rounds of TherOx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $15M | Debt – Conventional | – | – | |
| Jul 2015 | $16.81M | Series D | – | – | – |
| Sep 2014 | $1.04M | Series C | – | – | – |
| Nov 2013 | $5.6M | Series C | – | – | |
| Mar 2008 | $30M | Series C | – | DAG Ventures | |
| Jul 2005 | $30M | Series B | – | – | |
| Dec 2000 | $30M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in TherOx
TherOx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, ZOLL AEDs and Tekla Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Mid-stage venture capital investments and support for tech entrepreneurs. | dagventures.com | |||
Early, mid, and late-stage investments are made in science sectors. | newscienceventures.com | New York, United States | ||
A healthcare-focused investment firm supporting innovative company growth. | aperturevp.com | |||
Growth stage tech & life sciences focused VC firm funding companies in the US | icp.com | Menlo Park, United States | ||
Sector-agnostic investments in late-stage startups are made by Cross Creek. | crosscreek.vc | Salt Lake City, United States | ||
Medical devices and software for emergency care are developed. | 1983 | zoll.com | Chelmsford, United States | |
Operates as a funds investment management firm providing advisory services. | 1975 | wasatchfunds.com | Salt Lake City, United States | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States |
Investor details for TherOx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TherOx
4 dated milestones of TherOx across 24 years, from founding to its latest funding, stage changes and deals.
- Founded TherOx is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Debt – Conventional, of $15.0M.
- Exit Acquired by ZOLL AEDs.
Competitors of TherOx
TherOx has 3 listed competitors in our database, 2 of them funded. They include Precise Bio, Nirva Medical and Nininger Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| precise-bio.com | 2015 | Winston-salem, United States | $12M | 6 | Developer of integrated 3D printing and tissue-engineering platform | |
| nirvamedical.com | 2010 | Saint Paul, United States | $260,000 | Developer of a device to treat heart attack | ||
| niningermed.com | 2019 | Brea, United States | Technological solutions for structural heart failure patients are developed. |
Detailed competitors of TherOx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as TherOx (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Therox
Complete news archive for TherOx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TherOx
TherOx was founded in 1995 and raised its 1st funding round 5 years after it was founded.
TherOx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
TherOx is a funded company, having raised a total of $113.44M across 7 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Dec 2000.
TherOx has 17 employees.
TherOx is a private medical device company which has developed the super-saturated oxygen (SSO2) therapy system and cartridge. The intent of this therapy is to salvage damaged heart tissue by placing a high concentration of oxygen into the patients blood plasma and delivering it directly to the area impacted by the heart attack. It is used as a complement to percutaneous coronary intervention and stenting. The product is yet to receive FDA approval. The company is backed by Kleiner Perkins Caufield and Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners, DAG Ventures and Cross Creek Capital.
TherOx's top competitors include Precise Bio, Nirva Medical and Nininger Medical.
TherOx has 9 investors. Key investors include Kleiner Perkins, ZOLL AEDs, Tekla Capital Management, DAG Ventures, and New Science Ventures.
TherOx operates through Therox, Inc..
Yes. TherOx was acquired by ZOLL AEDs in June 2019.